Selank

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) was developed alongside Semax at the Institute of Molecular Genetics in Moscow. While Semax focuses on cognitive enhancement, Selank was optimized for anxiolytic properties combined with nootropic benefits.

Selank modulates GABAergic neurotransmission and influences the balance of T-helper cell cytokines, producing anxiolytic effects comparable to benzodiazepines but without sedation, dependence, or withdrawal. Clinical trials showed a 2x reduction in anxiety scores vs placebo with simultaneous improvement in cognitive metrics.

It also serves as an immunomodulator derived from tuftsin, enhancing NK cell activity and balancing pro/anti-inflammatory cytokine ratios. This dual anxiolytic-immunomodulatory profile is unique among available peptides.